HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials
Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.
Tyrosine Kinase Inhibitors Unresectable Hepatocellular Carcinoma Hepatocellular Carcinoma Transarterial Chemoembolization Launch Study Emerald 1 Study
Source: onclive.com